焦作义
•荣誉奖励
2023 甘肃省拔尖领军人才
2021 甘肃省科技进步二等奖
2018 甘肃省青年科技奖
2018 甘肃省医学科技奖
2016 甘肃省科技进步二等奖
2015 甘肃省医学科技奖
•研究兴趣
围绕“靶免治疗时代如何提升消化系统肿瘤5年生存率”健康中国2030规划重大目标，聚焦“胃癌/胰腺癌耐药机制及新药研发”开展系统性研究。
•代表成果
1. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B, Wang J, Guan X, Ye H, Yang J, Yu Z, Jiao Z*. Gastroenterology 2023, 164, 1232-1247.
2. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer. Ye H, Shi W, Yang J, Wang L, Jiang X, Zhao H, Qin L, Qin J, Li L, Cai W, Guan J, Yang H, Zhou H, Yu Z, Sun H, Jiao Z*. Cancer Res. 2023, 83, 3767-3782.
3. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, Cai W, Wen F, Jiang X, Zhang T, Ye H, Long B, Qin J, Shi W, Guan X, Yu Z, Yang J, Wang Q, Jiao Z*. Sci. Adv. 2022, 8, eabn3774.
4. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, Yu Z, Zhao L, Liu Y, Zhang X, Qin J, Ye H, Jiang X, Zhou H, Sun H, Jiao Z*. Nat. Commun. 2021, 12, 2812.
5. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H, Shi W, Wang Q, Luo C, Long B, Zhou H, Sun H, Jiao Z*. Oncogene 2021, 40, 1027-1042.
